Ensemble/Mosaic, a joint venture between Ensemble Real Estate Investments and Mosaic Development Partners, and Oxford Properties Group (“Oxford”), a leading global real estate investor, asset manager and business builder, have broken ground on 1201 Normandy Place, a speculative 137,000 square foot R & D lab building at the Navy Yard in Philadelphia. The project represents
Ensemble/Mosaic and Oxford Properties Group (“Oxford”) have entered into a strategic partnership which will, over time, own and develop up to 3 million square feet of life science properties at the Navy Yard in Philadelphia. The agreement includes Oxford’s investment in five existing life science assets owned by Ensemble Real Estate Investments, and Ensemble/Mosaic’s first
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further enhance the company’s Contract Testing, Development and Manufacturing Organization (CTDMO) business model by tripling the company’s previous
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with
Multidisciplinary Team Includes 13 Subject Matter Expert Consultants; More Than 50% are Certified Minority- and Women-owned Business Enterprises PIDC, Philadelphia’s public-private economic development corporation and master developer of the Philadelphia Navy Yard, in partnership with Ensemble Real Estate Investments and Mosaic Development Partners (“Ensemble/Mosaic”), today announced the selection of James Corner Field Operations (“Field Operations”) to
Renderings available HERE. PIDC, Philadelphia’s public-private economic development corporation, has selected a team comprised of Ensemble Real Estate Investments and Mosaic Development Partners as its development partner for 109 acres at the Philadelphia Navy Yard. Selection of the Ensemble/Mosaic team is the culmination of a year-long competitive process that attracted interest from more than 35
This week, PIDC President Anne Bovaird Nevins announced a Navy Yard leadership transition. Senior Vice President Prema Katari Gupta has accepted a new position at the Center City District and will leave PIDC after nearly five years of leading the Navy Yard team, and Kate McNamara, PIDC’s Vice President of Real Estate Services, has been
As a historic, thriving waterfront district in Philadelphia, the Navy Yard is bustling with 15k people, 175 companies, and hundreds of career opportunities for all! Take a look at these 20 Navy Yard businesses that you could work for in 2020!
The 95,000 square foot build-to-suit office and laboratory building for WuXi AppTec’s Advanced Therapies Business Unit (WuXi ATU), located at 400 Rouse Boulevard, is moving forward as expected.
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel.